征稿已开启

查看我的稿件

注册已开启

查看我的门票

已截止
活动简介

We are pleased to welcome all the interested participants to Neglected Tropical Diseases Conference: Current and Future Challenges during November 02-03, 2017 at Chicago, Illinois, USA. Tropical diseases 2017 welcomes all the members form universities, clinical examination foundations, research organizations ,biologists, scientists, researchers, academicians, entrepreneurs, research scholars and delegates from research labs, industries and healthcare sectors to be a part of the conference to share their knowledge on all parts of this rapidly expanded field and then, by providing a showcase of the research in this field and making the efforts to conquer this battle of Neglected Tropical diseases which is burden to our human society.

The conference focuses on the theme "Improved Health Protection Paybacks for all".

Tropical Diseases 2017 aims to provide scientific platform for face to face exchange of knowledge and research ideas across these concerns for endemic diseases which is claiming havocs around the globe every year. The conference is designed to give knowledge, ideas and to think out of the box. The aim of the conference is to promote research in the field of neglected tropical diseases with another goal to facilitate exchange of new ideas in these fields and to create a dialogue between scientists, practitioners, health organizations to come together and overcome and conquer this situation.

Neglected Tropical Diseases (NTDs) are a diverse group of communicable diseases which almost covers 18 infectious diseases that are caused by bacteria, parasites, or viruses that more or less affect the poor societies generally affect children and causes significant health and financial burdens and across the underdeveloped nations. They mostly affect populations who are living in poverty, without proper sanitation and in close touch with various infectious vectors and disease causing livestock and animals. NTDs are very common and sometimes fatal and they regularly infect humans. Over 150 countries, with almost over 1 billion people are currently infected and over 2 billion people at verge of risk and are responsible for millions of deaths and disabilities each year, around the globe. According to the reports from World Health Organization (WHO), the major diseases of concern are malaria, which affects more than one third of the world’s population, and have killing more than 1 million children every year; visceral leishmaniasis, affecting about 12 million people and Chagas disease, affecting 18 million people in Latin America alone which sleeping sickness (African trypanosomiasis), which affects half a million people each year.

These diseases are generally preventable and treatable through control of the insects that carry these diseases, improved sanitation, fresh and clean water quality, and the proper health awareness along with the efficient delivery of drug treatments. Controlling NTDs is very prominent and requires major steps which would not only reduce disease burden but would also improve maternal health, reduce childhood mortality, reduce malnutrition, and help to improve school attendance.

Of the 850 new therapeutic products registered in 2000–2011, only 5 (0.6%) were indicated for NTDs, none of them being a new chemical entity (NCE) or vaccine. It is quite surprising that Ebola is officially classed as a ‘neglected tropical disease’ although recent outbreaks are  the worst on records and interestingly  between 1976 and 2013 there occurs 26 outbreaks of the virus, mainly occurred in sub-Saharan African nations, resulting in a total of around 1,710 cases. We can clearly see the comparison and level of difference between Ebola outbreak and the current Chikungunya outbreak and the level of media and news hype that estimated to have infected around 900,000 people in Americas only.

In January 2012, WHO, the Bill & Melinda Gates Foundation, political members from  several states, Managing Directors from the  various pharmaceutical industry provided  a vision  known as the London Declaration on Neglected Tropical Diseases. They pledged to sustain, expand, and extend the drug supply; (b) accelerate research and development for new treatments; and (c) increase funding to improve implementation to control or eliminate 10 NTDs.

The U.S. Agency for International Development has recently announced a five year, $100 million fund to provide some major preventive drugs for 40 million people, while Geneva Global has committed $8.8 million for preventive chemotherapy in Rwanda and Burundi which will help in combating these burdens.

The Bill and Melinda Gates Foundation have awarded $47 million to acknowledge and discuss the prominent questions regarding research and development for effective amalgamation. However, these awards are not so sufficient enough compared to overall costs required to meet up the needs in the areas of sub-Saharan Africa and elsewhere around the globe. It is estimated that approximately $1 billion to $2 billion fund must be needed within a five year program to control or somewhat eliminate the major neglected tropical diseases in sub-Saharan Africa.

Why to attend??

With members from around the world focused on learning more about the tropical diseases treatment and their management. This conference will provide the best platform and the best occasion to outreach the great gathering of participants from around the world. This scientific stage will provide an opportunity to the scientists, researchers to conduct presentations, exchange and update knowledge about the current situation of neglected tropical diseases treatment and receive recognition on global platform and join hands for this global human cause.

征稿信息

重要日期

2017-09-11
初稿截稿日期

征稿范围

Session 01: Neglected Tropical Diseases

  • Bacterial infectious diseases

  • Viral infectious diseases

  • Protozoa infectious diseases

  • Helminths infectious diseases

  • Deadly infectious diseases

  • Mosquito borne diseases

  • Blood borne infectious diseases

Session 02: Global Trends in Emerging Neglected Tropical Diseases

  • Risk Factors and Challenges

  • Support and funding

  • Geographic, Environmental, and Social Determinants

  • Ecology and Economic Development

Session 03: Tropical Diseases: Facts and Figures

  • Economic impact

  • Drug development

  • Diagnostic tools

  • Technical feasibility

Session 04: Zika Virus: The Next Emerging Threat?

  • Addressing this critical topic

  • Transmission, detection, control and prevention

  • Intrinsically disordered side of the Zika virus proteome

  • Brain abnormalities in fetuses

  • Development of vaccine candidates

  • Countering the Zika epidemic

Session 05: Ebola Virus Epidemic

  • Outbreak, Symptoms, and Treatment

  • Clinical prognosis and diagnostic tests

  • Cause and prevention

  • Risk factors

  • Latest research 

Session 06: Most Common NTDs: Causes and Treatments

  • Guinea Worm Disease

  • Lymphatic Filariasis

  • Onchocerciasis

  • Schistosomiasis

  • Trachoma

  • Soil-Transmitted Helminths

Session 07: Drug Discovery for Neglected Tropical Diseases

  • Identification and screening of libraries

  • Pharmacology and pharmacodynamics

  • Target-based approach

  • Phenotypic approaches

  • Medicinal chemistry approach

Session 08: Pathogenesis and Immunity

  • Pathogens and immune system: spread, persistence and transmission

  • Microbial adherence

  • Invasion of host cells and intracellular survival

  • Evasion of immune responses

  • Host interactions and system biology

  • Vaccine development

Session 09: Emergent Arboviruses: Dengue and Chikungunya

  • Outbreaks

  • Diagnosis

  • Symptoms and pathophysiology

  • Molecular genetics and current research

  • Therapeutic measures and vaccination

  • Prevention, control and cure

  • Public awareness

Session 10: Technical Challenges for Neglected Tropical Diseases Vaccines

  • Antigen discovery

  • Process development

  • Preclinical development

  • Clinical trials in resource-poor settings

  • The immune response to NTD infection

Session 11: Advances in Vector Biology Research

  • Challenges in prevention of vector-borne diseases

  • Detection of molecular targets for drug development

  • Novel diagnostics strategies

  • Antiviral and antimicrobial treatment

Session 12: Rise of Multiomics: Integrative approach

  • Genome annotation

  • Proteomics

  • RNA isolation

  • cDNA sequencing

  • Gene expression analysis

  • High-performance liquid chromatography with high-resolution tandem mass spectrometry

  • Transcriptomics: next-generation sequencing

  • Immunomic microarrays

Session 13: Translational Strategies to Prevent Neglected Tropical Diseases

  • Basic orientated clinical research

  • Disease orientated clinical research

  • Patient orientated clinical research

Session 14: New Technologies for Achieving NTD Elimination

  • Preventive chemotherapy

  • New NTD drugs

  • New NTD vaccines

  • Anthelminthic vaccines

  • Kinetoplastid vaccines

  • Plant-based vaccines against neglected tropical diseases

Session 15: Dynamics and Consequences of Antimicrobial Resistance

  • Genetic modification

  • Multi drug resistance

  • Antibiotic resistance

  • Antimicrobial resistance mechanisms

  • Resistance to antibacterial, antifungal, anti-viral agents, anti-parasitic, and anti-mycobacterial

Session 16: Novel Strategies Involved in Neglected Tropical Diseases

  • Proteasome protein complex method

  • Broad spectrum antibacterial agents

  • Collaborative drug discovery

  • Bioactivity testing and screening

  • Screening of natural products

  • Bioluminescent live-imaging technique

留言
验证码 看不清楚,更换一张
全部留言
重要日期
  • 会议日期

    11月06日

    2017

    11月07日

    2017

  • 09月11日 2017

    初稿截稿日期

  • 11月07日 2017

    注册截止日期

主办单位
Allied Academies
移动端
在手机上打开
小程序
打开微信小程序
客服
扫码或点此咨询